177 results about "Human breast" patented technology

The invention relates to a triple-hole paper-based three-dimensional cell culture chip as well as a preparation method and application thereof. The chip comprises a paraffin hydrophobic region and a paper-based hydrophilic region. The preparation method mainly comprises the following steps: 1) designing a mask plate; 2) cutting the mask plate by laser; and 3) preparing the triple-hole paper-based chip by hot pressing. The thickness of the chip is 100-200 [mu] m, the porous fiber structure of the paper-based material allows transportation of oxygen and waste, and a three-dimensional microenvironment for in-vivo cell growth can be simulated. Meanwhile, a transparent and liquid-tight supporting layer is fused on the lower layer of the paper-based chip, so that leakage of cells inoculated on the upper layer of the paper-based chip is avoided. The paper-based chip is embedded into a 6-pore plate, and bladder cancer cells (5637), mouse astrocytoma (U87) and human breast cancer cells (MCF-7) are inoculated in a paper-based hydrophilic region respectively. The cell compatibility of the paper-based chip and the growth behaviors of three different types of cells in three-dimensional paper fibers are investigated. It is proved that the chip can be used for researching three-dimensional construction and growth of human and mammalian cells, and the difference between three-dimensional culture and two-dimensional culture is revealed by detecting the proliferation capacity and survival rate of different cells.

The invention provides a beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative as well as a preparation method and application thereof, and belongs to the technical field of organic chemical synthesis. The beta '-thio-alpha, beta-unsaturated gamma-lactam derivative has a structure as shown in a formula I. According to the method disclosed by the invention, cesium carbonate is taken as alkali, and a molecular skeleton of the beta'-thio-alpha, beta-unsaturated gamma-lactam derivative is constructed through free radical coupling and olefin isomerization processes under the condition of blue light irradiation. Bioactivity evaluation shows that the beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative prepared by the method disclosed by the invention has an inhibition effect on MDA-MB-231 human breast cancer cells.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 3-sulfamoyl benzamide compound as well as a preparation method and application thereof. The 3-sulfamoyl benzamide compound has a structure as shown in a formula I. In the formula I, X is chlorine or trifluoromethyl; r1 and R2 are independently C1-4 alkyl or R1, R2 and N atoms connected with R1 and R2 jointly form a heterocyclic group, and the heterocyclic group is a substituted or unsubstituted five-membered or six-membered heterocyclic group; and when the heterocyclic group is a substituted heterocyclic group, the substituent group in the substituted heterocyclic group is one or more of C1-4 alkyl, phenyl and acetyl. The 3-sulfamoyl benzamide compound disclosed by the invention has a remarkable proliferation inhibition effect on HCT116 colon cancer cells, HeLa human cervical cancer cells, MDA-MB-231 human breast cancer cells and A375 human malignant melanoma cells.

The present invention belongs to the technical field of undergarments, and discloses a brassiere, which includes a pair of bra cup cores, and one or more body fabric panel attached with the bra cup cores on the front. The brassiere is formed by connecting both sides via side band fabric panel which are warped to a back of the body, and is sealed and fastened via fastening buckles with or without shoulder straps or fabric panel to support, uplift, and control human breasts. The present invention aims at restoring natural and comfortable beauty of the human breasts via the seamless brassiere fused with the bra cup cores with the 3D bonding technology to minimize joining and stitching causing the itch or discomfort for wearers. The 3D bonding technology of the present invention can be used for the shapes, profiles, and peripheries of different types of 3D bra cup core.

Disclosed is an anticancer composition using a flavone derivative. In the present invention, the flavone derivative exhibits cytotoxicity against: H827, H1299, H522, and A549, which are human non-small cell lung cancer cell lines; MCF-7, which is a human breast cancer cell line; and PANC-1, which is a human pancreatic cancer cell line, in a time-dependent manner and in a treatment concentration-dependent manner, and not only exhibits a synergistic effect when used in combination with other conventional anticancer agents, such as osimertinib, which is an anticancer agent targeting for lung cancer, tamoxifen, which is a hormone agent against breast cancer, and gemcitabine, which is a cytotoxic anticancer agent against pancreatic cancer, but also exhibits the effect of synergistically inhibiting the expression of HIF-1α when used alone or in combination with an existing anticancer agent.

The invention discloses a 5-substituted-3-(arylaminoethyl) benzoxazolone compound and a preparation method and application thereof.The compound takes CO2 as a carbonyl source, the preparation method is simple, raw materials are easy to obtain, and the compound has a good anti-cancer effect on the activity of cancer cells and particularly has a remarkable anti-cancer effect on the cancer cells such as HCCLM3 (human hepatoma carcinoma cells) and MCF-7 (human breast cancer cells).

A method of treating cancer cells includes exposing the cancer cells to a ZrO2 / CaSiO3 / g-C3N4 nanocomposite material. The ZrO2 / CaSiO3 / g-C3N4 nanocomposite material comprises spherical metal oxide nanoparticles comprising a ZrO2 phase and a CaSiO3 phase dispersed on a matrix of g-C3N4 nanosheets, wherein the spherical metal oxide nanoparticles have an average particle diameter in a range from 3 to 18 nm, and wherein the ZrO2 / CaSiO3 / g-C3N4 nanocomposite material has a percent inhibition for human breast carcinoma (MCF-7) cells greater than or equal to 80% inhibition in an in-vitro cellular viability assay.

The invention discloses an azacyclo-derived polyaryl methane anti-tumor compound and a synthesis method thereof. The chemical structural formula of the compound is shown as a formula 3. The synthesis method comprises the following steps: adding 2-pyrrole derivative indole and aromatic aldehyde as reaction raw materials into toluene, stirring and reacting for 6-10 hours at 25 DEG C under the catalysis of binaphthyl phosphoric acid, tracking the reaction by TLC until the reaction is complete, filtering, concentrating and purifying to obtain the 2-pyrrole derivative indole. According to the azacyclo-derived polyaryl methane compound synthesized by the invention, a biological activity test shows that the derivative has relatively high sensitivity and very strong cytotoxic activity on human breast cancer cells MCF-7. The method is conventional in reaction condition, mild and simple in reaction process, low in cost and suitable for industrial large-scale production, and the application range of the method is widened; according to the method, various substrates are used as reactants, and products with various structures are obtained. # imgabs0 #

The invention belongs to the technical field of machine learning, and provides a multi-model integrated prediction method and system for human breast cancer cytotoxicity caused by ionic liquid, and the main scheme is as follows: collecting experimental data and preprocessing the experimental data; splicing the quantifiable features to form an original feature matrix; performing feature dimension reduction processing on the original features to form an input feature matrix; taking the input feature matrix as input data, training a random forest, XGBoost and MLP basic machine learning model and carrying out model parameter adjustment, carrying out model integration on the trained basic machine learning model based on a weighted average fusion strategy, and selecting an optimal integrated model; evaluating the trained basic machine learning model, and applying the optimal integrated model to prediction of the human breast cancer cell toxicity of the ionic liquid of a new sample; and carrying out model deployment on the trained basic machine learning model and the selected optimal integrated model.

The application belongs to the technical field of medicine, and relates to N-methyl-2-(9-oxoacridin-10(9H)-yl)acetamide compounds and a preparation method and application thereof. The preparation method of the compound is as follows: taking o-aminobenzoic acid as a starting material, performing substitution reaction, condensation reaction, alkylation reaction and hydrolysis reaction to generate a key intermediate acridone acetic acid, and finally performing condensation reaction on the acridone acetic acid and substituted pyrimidine in the presence of TCFH and NMI condensing agents to obtain the target compound. The preparation method of the N-methyl-2-(9-oxoacridin-10(9H)-yl)acetamide compound provided in the application is simple and feasible, and good results are shown in in-vitro anti-tumor activity tests, and the compound has excellent anti-proliferation ability on human breast cancer cells BT-549 and MDA-MB-231 in particular.

The invention belongs to the technical field of pharmacy, and particularly relates to application of polycyclic alkaloid in preparation of an anti-breast cancer drug, and the polycyclic alkaloid is 1, 2a, 7-trimethyl-5-tosyl-1, 2, 2a, 3, 4, 5-hexahydropyrrolo [4, 3, 2-de] quinoline. The polycyclic alkaloid compound is applied to preparation of anti-breast cancer drugs, the effect of inhibiting growth of breast cancer cells is remarkable, and the efficacy of the polycyclic alkaloid compound is far better than that of a positive drug ML162 aiming at EC50 (mu M) + / -S.D = 9.04 + / -0.37 of HCC1937 human breast cancer cells.

The invention discloses an application of an ARRB1 inhibitor in preparation of a tumor drug resistance reversal agent or a tumor drug sensitizer. It is found that by reducing ARRB1 expression, the sensitivity of human breast cancer cells to etoposide can be improved, the drug resistance of breast cancer etoposide can be reversed, and an ARRB1 inhibitor can be combined with an anti-tumor drug etoposide for use to improve the treatment effect. The invention provides a new direction for research and development of drugs for overcoming breast cancer treatment drug resistance, and has important clinical application value and development value.

A method of inhibiting a cancer cell growth includes contacting the cancer cell with a Cu2(OH)3NO3 / CaSiO3@g-C3N4 nanocomposite material containing graphitic carbon nitride (g-C3N4), copper hydroxide nitrate (Cu2(OH)3NO3) and calcium silicate (CaSiO3), achieving an inhibition efficiency on human breast carcinoma (MCF-7) and human hepatocellular carcinoma (HepG-2) cell growth of greater than 95% in an in-vitro cellular viability assay.

The BTK-C isoform is expressed in human breast and prostate cancer cells and it plays a crucial role in epithelial cancer cell survival. BTK-C has a 34 amino acid extension to the n-terminus that facilitate it being palmitoylated on two cysteine residues. This modification localizes BTK-C closer to the cell membrane where it plays a role in improving cancer cell survival, as compared to BTK-A. BTK-C is not found to be expressed in healthy adult cells, whereas BTK-A is necessary for immune cell production. Disclosed herein are alternative kinases besides BTK having similar attributes, which present therapeutic opportunities for the treatment of cancers, especially for solid tumors.

The invention discloses a breast pump. The breast pump comprises at least one detection module, a processing module, a breast pumping shield, a breast pumping channel part and a negative pressure mechanism, the breast suction shield comprises a flange used for being attached to a human breast body. The breast sucking channel part is in sealed connection with the breast sucking shield and is used for accommodating a nipple and allowing milk to flow; the negative pressure mechanism is used for directly or indirectly applying negative pressure into the breast pumping channel part; the detection module is used for detecting brightness change caused by movement of a target object in the breast pumping shield or the breast pumping channel part and generating detection data, and the processing module is used for determining breast pumping related parameters according to the detection data. The detection module generates the detection data by detecting the brightness change caused by the movement of the target object, and the generated detection data is less influenced by the individual difference of the mother, so that the measurement interference caused by the difference of different individuals can be effectively avoided, and the finally determined breast pumping related parameters can be more accurate.

This invention relates to drug-resistant breast cancer cells and their applications, belonging to the field of tumor cell technology. The drug-resistant breast cancer cells of this invention are human mammary ductal carcinoma cells T47DR and / or human breast cancer cells MCF7R. The human mammary ductal carcinoma cells T47DR were deposited at the Guangdong Provincial Microbial Culture Collection Center on October 25, 2024, with accession number GDMCC No: 65348; the human breast cancer cells MCF7R were deposited at the same center on October 25, 2024, with accession number GDMCC No: 65347. This invention demonstrates that the clonogenic ability, migration ability, anti-apoptotic ability, and spheroidization ability of drug-resistant breast cancer cells are significantly enhanced. They can form tumors independently of estrogen and metastasize throughout the body in a short period of time. The tumor stemness of the drug-resistant cells is enhanced, and they exhibit resistance to apelexifen and / or tamoxifen.

The present invention relates to the technical field of pharmaceutical compounds and specifically discloses a selenocyanine pregnenol ketamide compound having the following general structural formula: #imgabs0#. The selenocyanine pregnenol ketamide compound of the present invention exhibits strong inhibitory activity against human breast cancer cells, cervical cancer cells, ovarian cancer cells, and human liver cancer cells. Furthermore, the selenocyanine pregnenol ketamide compound of the present invention also exhibits strong inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The selenocyanine pregnenol ketamide compound of the present invention has low toxicity to humans and exhibits strong inhibitory effects against cancer cells and various drug-resistant bacteria at low concentrations. It can be used to prepare cancer treatment drugs and as an antibacterial agent against drug-resistant bacteria.

[Problem] The present invention provides an inhibitor such as an MDA-MB-231 cell proliferation inhibitor containing DHMBA as an active ingredient, the inhibitor affecting the proliferation, metastatic activity, and bone microenvironment of MDA-MB-231 cells in vitro, and making it possible to provide a useful therapeutic strategy for human breast cancer. [Solution] The present invention is characterized by having the effect of inhibiting the proliferation of human breast cancer MDA-MB-231 cells containing 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient.

1. The name of this design product: Breast Coil. 2. Purpose of this design product: This design product is used as auxiliary diagnostic equipment for medical imaging magnetic resonance imaging, and accurately images the types and lesions of diseases in the human breast area. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The invention discloses a flavonoid enantiomer compound extracted from Epimedium sagittatum and its preparation method and application. The preparation method comprises the following steps: crushing Epimedium sagittatum to prepare a paste, suspending the paste with water, extracting the paste with petroleum ether, dichloromethane, ethyl acetate and n-butanol respectively to obtain extracts of each part, performing gradient elution separation by silica gel column chromatography, combining similar parts according to the color development results of thin layer chromatography (TLC) to obtain multiple polar segments; chromatographing the target polar segment and performing gradient elution to obtain multiple components, and then combining similar components by thin layer chromatography (TLC) spot plate absorption to obtain multiple sub-components; eluting and purifying the target sub-components, collecting fractions with different retention times, and drying to obtain four compounds respectively. The four compounds have a significant inhibitory effect on the cell viability of human breast cancer MCF-7 cells and have anti-breast cancer activity. The four compounds can be used in the preparation of drugs for treating breast cancer, with huge social and economic benefits.

The present invention discloses the application of aspirin combined with abemacili or in combination with other drugs in the treatment of breast cancer, and belongs to the technical field of tumor therapeutic drugs. The present invention firstly finds that, compared with the single application of abemacili, the combined or coordinated use of aspirin and abemacili can significantly inhibit the proliferation of breast cancer MCF7 and MDA-MB-231 cells and promote the apoptosis of breast cancer MCF7 and MDA-MB-231 cells, and the effect of the combined use of aspirin and abemacili is significantly better than the effect of the single application of abemacili or aspirin; compared with the single application of abemacili, the toxicity to normal human breast MCF10A cells is not enhanced, and it is expected to be used for the treatment of breast cancer, and provide a new drug combination for reducing the cost of breast cancer treatment, improving the treatment effect, and alleviating the suffering of patients.

Disclosed in the present invention are a PARP1 / CDK6 dual-target inhibitor, and a preparation method therefor and the use thereof. The PARP1 / CDK6 dual-target inhibitor is a compound having a structure represented by formula I, or a pharmaceutically acceptable salt or solvate thereof, wherein L is selected from or , and R is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, sulfhydryl, cyano, nitro, methoxy, a C1-C8 alkyl, or a C3-C8 cycloalkyl. The PARP1 / CDK6 dual-target inhibitor of the present invention exhibits good effects against human breast cancer cells, and maintains a good in vitro enzyme inhibitory activity against CDK6 and PARP1. Disclosed in the present invention is the use of a CDK6 / BRD4 dual-target inhibitor in the preparation of a drug for treating PARP1 / CDK6-mediated diseases. Disclosed in the present invention is the use of a PARP1 / CDK6 dual-target inhibitor in the preparation of a drug for treating or preventing triple-negative breast cancer.

The invention discloses an antibody or an antigen binding fragment specifically binding to trop2. The antibody or the antigen binding fragment comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequence of the HCDR1 is as shown in SEQ ID NO.1, the amino acid sequence of the HCDR2 is as shown in SEQ ID NO.2, the amino acid sequence of the HCDR3 is as shown in SEQ ID NO.3, the amino acid sequence of the LCDR1 is as shown in SEQ ID NO.4, the amino acid sequence of the LCDR2 is as shown in SEQ ID NO.5, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO.6. The expression condition of trop2 in human breast cancer and pancreatic cancer cell membrane tissue samples can be detected through an immunohistochemical method, and the adjoint diagnostic kit for the humanized trop2 antibody coupling medicine has the advantages of assisting in precise medication and avoiding invalid treatment.

The utility model relates to the technical field of brassiere products, in particular to a thin cup brassiere structure with lateral contraction and ventilation functions, each cup is of a double-layer structure with an inner layer and an outer layer, and an outer layer fabric is arranged on the outer layer of each cup; the two cup inner layers are symmetrically arranged, the center position connecting piece is connected with the two cup inner layers, and each cup inner layer comprises an inner layer side wing end structural piece, a cup mat and an inner layer center position end structural piece which are sequentially arranged in the direction from the wing position piece to the center position connecting piece; the outer-layer fabric, the inner-layer side end structural member, the cup mat and the inner-layer center end structural member are connected into a whole through supporting members. According to the bra, the cups with the inner and outer double-layer structures are arranged, the inner layers of the cups are of the longitudinal three-piece type split structures, the area and the breathability are optimally designed according to different functions of different areas of the cups, and the connecting structure and the size are improved, so that the requirements of the bra product for shielding the nipples and the overall breathability when the bra product is worn are met; and the functional effects of laterally folding and upwards supporting the breasts of the human body and the like are achieved.

The invention relates to the field of medicinal chemistry and cosmetics, in particular to a curcumin derivative and a preparation method and application thereof. The curcumin derivative provided by the invention has a structure as shown in a formula I. Compared with parent curcumin, the curcumin derivative provided by the invention not only improves the anti-oxidation effect, but also has the whitening and anti-aging effects which are not possessed by the parent curcumin, so that the application field range is greatly widened, and the curcumin derivative has wide application in the field of cosmetics. Moreover, the curcumin derivative provided by the invention has a good anti-tumor effect on brain glioma, human breast cancer, human lung cancer or human non-small cell lung cancer, and has wide application in the field of medicines.

This utility model discloses a two-piece bra cup with longitudinal segmentation and a bra having the cup, including a first longitudinal piece and a second longitudinal piece, wherein the thickness of the first longitudinal piece is less than the thickness of the second longitudinal piece; the first longitudinal piece is located on the side of the cup near the center gore, and the second longitudinal piece is located on the side of the cup away from the center gore; the edge of the second longitudinal piece near the first longitudinal piece is a smooth curve that rises towards the first longitudinal piece, and this edge extends from the bottom of the cup to the ear area; the first longitudinal piece covers the nipple area, and the edges of the first and second longitudinal pieces close to each other are spliced ​​and fixed to make the cup have a three-dimensional bowl-shaped structure corresponding to the curvature of the human breast. The bra cup provided by this utility model has the advantages of good lifting effect, strong side push and gathering, leak prevention, breathability and comfort, and making it appear smaller when worn.

Isoprenyl flavonoid compounds extracted from Epimedium sagittatum and preparation method and application thereof, the preparation method is: crushing Epimedium sagittatum to paste, suspending with water, extracting with petroleum ether, dichloromethane, ethyl acetate and n-butanol respectively to obtain various parts of extract, using silica gel column chromatography to separate by gradient elution, according to the TLC coloration result, similar parts are combined to obtain multiple polarity sections; chromatograph the target polarity section, gradient elution, obtain multiple components, then combine similar components by TLC point plate absorption to obtain multiple component groups; elute and purify the target component group, collect the flow fraction with different retention time, dry, and obtain two compounds respectively, which have significant inhibitory effect on the cell viability of human breast cancer cell MCF-7, have anti-breast cancer activity, and can be applied to prepare breast cancer treatment drugs, with huge social and economic benefits.

The invention discloses a polyphenol derivative as well as a preparation method and application thereof. Pharmacological studies prove that the polyphenol derivative L96-2 provided by the invention can effectively inhibit proliferation of human breast cancer cell lines MCF-7 and MDA-MB-231 and a human nasopharyngeal carcinoma cell line C666-1, and the inhibitory activity of the polyphenol derivative L96-2 is obviously higher than that of parent compounds icaritin and isatin of the polyphenol derivative L96-2. Meanwhile, the L96-2 can be used for effectively inducing apoptosis of the MCF-7 cells. The polyphenol derivative L96-2 provided by the invention has a very good inhibition effect on breast cancer and nasopharynx cancer cells and has a very good development value, and the technology also provides a new thought and approach for synthesis and antitumor research of polyphenol derivatives. The preparation method provided by the invention has the advantages of simplicity, cheap and easily available raw materials, no special requirements on production equipment, easiness in operation, low cost and easiness in realization of industrial production.

The invention discloses a feeding bottle nipple simulating human breasts, and relates to the technical field of infant feeding appliances. The feeding bottle comprises a feeding bottle body, one side of the feeding bottle body is in threaded connection with a nipple, one side of the feeding bottle body is provided with a holding mechanism, and the holding mechanism comprises a supporting plate arranged on one side of the feeding bottle body in a sleeving mode. By means of the design of the double-layer valve plate assembly, regulation and control over the flow speed of milk are achieved, when a baby slightly sucks the milk, the thin and soft inner-layer valve plate deforms and is opened firstly, the milk slowly flows into the milk inlet pipe only through the milk inlet through hole, the low-speed state in the initial stage of breast feeding is simulated, the thick outer-layer valve plate is pushed away along with the increase of the sucking force, and the milk flows into the milk inlet pipe. The milk is rapidly output from the large-diameter channel to meet the hunger requirement, the physiological feature of'lactation reflex 'of breast milk is reproduced through the gradient deformation characteristic of the valve plate in the movement process, the bucking risk caused by the constant flow speed of a traditional nipple is effectively avoided, and the feeding comfort and efficiency are effectively improved.

A method of inhibiting cell growth in a cancer includes contacting a graphite-phase carbon nitride copper oxide and magnesium aluminum oxide (g-C3N4@CuO / MgAl2O4) nanocomposite with the cancer to inhibit growth of the cancer. The g-C3N4@CuO / MgAl2O4 nanocomposite comprises a graphite-phase carbon nitride (g-C3N4) in an amount of 2 to 18 percent by weight (wt. %), copper oxide in an amount of 1 to 10 wt. %, and magnesium aluminum oxide (MgAl2O4) in an amount of 75 to 95 wt. % based on a total weight of the g-C3N4@CuO / MgAl2O4 nanocomposite. The cancer includes cells from a cell line selected from a group consisting of a human hepatocellular carcinoma (HepG-2) cell line and a human breast carcinoma (MCF-7) cell line.